Ingrid Glimelius, MD, PhD, a senior lecturer and assistant professor in the Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology at Uppsala Universitet, discusses the lasting effects of lymphoma treatments.
Ingrid Glimelius, MD, PhD, a senior lecturer and assistant professor in the Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology at Uppsala Universitet, discusses the lasting effects of lymphoma treatments.
According to Glimelius, physicians should be mindful about how they surveille patients as some efforts may cause more worries. It is common for things to happen as a patient ages. Additionally, oncologists should coach patients on preventative measures they can take to lower their risk of long-term complications.
0:08 | Things happen as we grow older, and we would don't want to harm people by controlling them and causing more worries. So, we have to direct our interventions where we can really prevent things. For example, if you have been given radiotherapy to the breast and you're a young female, an MRI of the breast in the long run, then you can maybe detect, if there is an early breast cancer, you can detect it and you can remove it and the woman can be saved. So that is one thing. And also measures for primary prevention. For example, if you have had this intensive chemotherapy or radiotherapy, you shouldn't be smoking. I mean, you shouldn't anyway, but it's even more important to avoid smoking and advice around those factors is also important. And then of course, we have to meet the patients where they are, what are the problems they are burdened with? And what can we help them with?
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Later-Line CD19 and Bispecific Therapies Considered After CAR T
October 1st 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
Read More
Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL
September 16th 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether participants with use this treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More